Literature DB >> 17900257

Predictors of all-cause mortality for patients with chronic Chagas' heart disease receiving implantable cardioverter defibrillator therapy.

Augusto Cardinalli-Neto1, Reinaldo B Bestetti, José A Cordeiro, Vanessa C Rodrigues.   

Abstract

BACKGROUND: Implantable Cardioverter Defibrillators (ICD) have sporadically been used in the treatment of either Sustained Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) in Chagas' disease patients. This study aimed at determining predictors of all-cause mortality for Chagas' disease patients receiving ICD therapy. METHODS AND
RESULTS: Ninety consecutive patients were entered the study. Mean left ventricular ejection fraction was 47 +/- 13%. Twenty-five (28%) patients had no left ventricular systolic dysfunction. After device implantation, all patients were given amiodarone (mean daily dose = 331, 1 +/- 153,3 mg), whereas a B-Blocking agent was given to 37 (40%) out of 90 patients.
RESULTS: A total of 4,274 arrhythmias were observed on stored electrogram in 64 (71%) out of 90 patients during the study period; SVT was observed in 45 out of 64 (70%) patients, and VF in 19 (30%) out of 64 patients. Twenty-six (29%) out of 90 patients had no arrhythmia. Fifty-eight (64%) out of 90 patients received appropriate shock, whereas Antitachycardia Pacing was delivered to 58 (64%) out of 90 patients. There were 31 (34%) deaths during the study period. Five patients were lost to follow up. Sudden cardiac death affected 2 (7%) out of 26 patients, whereas pump failure death was detected in the remaining 24 (93%) patients. Number of shocks per patient per 30 days was the only independent predictor of mortality.
CONCLUSION: Number of shocks per patient per 30 days predicts outcome in Chagas' disease patients treated with ICD.

Entities:  

Mesh:

Year:  2007        PMID: 17900257     DOI: 10.1111/j.1540-8167.2007.00954.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  18 in total

Review 1.  Chagas heart disease: report on recent developments.

Authors:  Fabiana S Machado; Linda A Jelicks; Louis V Kirchhoff; Jamshid Shirani; Fnu Nagajyothi; Shankar Mukherjee; Randin Nelson; Christina M Coyle; David C Spray; Antonio C Campos de Carvalho; Fangxia Guan; Cibele M Prado; Michael P Lisanti; Louis M Weiss; Susan P Montgomery; Herbert B Tanowitz
Journal:  Cardiol Rev       Date:  2012 Mar-Apr       Impact factor: 2.644

2.  Chagas Heart Failure in Patients from Latin America.

Authors:  Reinaldo B Bestetti
Journal:  Card Fail Rev       Date:  2016-11

Review 3.  Diagnosis and Management of Chagas Cardiomyopathy in the United States.

Authors:  Lillian Benck; Evan Kransdorf; Jignesh Patel
Journal:  Curr Cardiol Rep       Date:  2018-10-11       Impact factor: 2.931

Review 4.  Diagnosis and management of Chagas disease and cardiomyopathy.

Authors:  Antonio L Ribeiro; Maria P Nunes; Mauro M Teixeira; Manoel O C Rocha
Journal:  Nat Rev Cardiol       Date:  2012-07-31       Impact factor: 32.419

5.  Fragmented surface ECG was a poor predictor of appropriate therapies in patients with Chagas' cardiomyopathy and ICD implantation (Fragmented ECG in CHAgas' Cardiomyopathy Study).

Authors:  Adrian Baranchuk; Francisco Femenia; Juan Cruz López-Diez; Claudio Muratore; Mariana Valentino; Enrique Retyk; Nestor Galizio; Darío Di Toro; Karina Alonso; Wilma M Hopman; Rodrigo Miranda
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-09-09       Impact factor: 1.468

6.  Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors.

Authors:  Ester C Sabino; Antonio L Ribeiro; Vera M C Salemi; Claudia Di Lorenzo Oliveira; Andre P Antunes; Marcia M Menezes; Barbara M Ianni; Luciano Nastari; Fabio Fernandes; Giuseppina M Patavino; Vandana Sachdev; Ligia Capuani; Cesar de Almeida-Neto; Danielle M Carrick; David Wright; Katherine Kavounis; Thelma T Goncalez; Anna Barbara Carneiro-Proietti; Brian Custer; Michael P Busch; Edward L Murphy
Journal:  Circulation       Date:  2013-02-07       Impact factor: 29.690

Review 7.  Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy.

Authors:  Claudio A Muratore; Adrian Baranchuk
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

8.  First appropriate implantable defibrillator shocks in patients with Chagasic heart disease

Authors:  Luis G García-Chamorro; Ezequiel J Zaidel; Lara Gheco; Matías A Oliva; Alejandro de-la-Vega; Agustín Orosco; Juan Armentano; Álvaro Sosa-Liprandi
Journal:  Arch Cardiol Mex       Date:  2022-07-01

9.  Mode of death on Chagas heart disease: comparison with other etiologies. a subanalysis of the REMADHE prospective trial.

Authors:  Silvia M Ayub-Ferreira; Sandrigo Mangini; Victor S Issa; Fátima D Cruz; Fernando Bacal; Guilherme V Guimarães; Paulo R Chizzola; Germano E Conceição-Souza; Fabiana G Marcondes-Braga; Edimar A Bocchi
Journal:  PLoS Negl Trop Dis       Date:  2013-04-25

10.  Autonomic dysfunction and beta blocker therapy in Chagas heart disease.

Authors:  Reinaldo B Bestetti; Augusto Cardinalli-Neto
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.